Emergent BioSolutions Inc (EBS)
1.95
-0.23
(-10.55%)
USD |
NYSE |
Apr 25, 16:00
1.97
+0.02
(+1.03%)
After-Hours: 20:00
Emergent BioSolutions Free Cash Flow: -257.90M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -257.90M |
| September 30, 2023 | -209.40M |
| June 30, 2023 | -358.70M |
| March 31, 2023 | -279.50M |
| December 31, 2022 | -149.90M |
| September 30, 2022 | 63.20M |
| June 30, 2022 | 126.60M |
| March 31, 2022 | 77.60M |
| December 31, 2021 | 96.10M |
| September 30, 2021 | 22.90M |
| June 30, 2021 | 120.90M |
| March 31, 2021 | 310.40M |
| December 31, 2020 | 395.00M |
| September 30, 2020 | 271.90M |
| June 30, 2020 | 194.00M |
| March 31, 2020 | 51.30M |
| December 31, 2019 | 101.10M |
| September 30, 2019 | -171.50M |
| June 30, 2019 | -5.20M |
| March 31, 2019 | 65.70M |
| December 31, 2018 | -30.30M |
| September 30, 2018 | 221.37M |
| June 30, 2018 | 95.63M |
| March 31, 2018 | 119.33M |
| December 31, 2017 | 153.30M |
| Date | Value |
|---|---|
| September 30, 2017 | 55.62M |
| June 30, 2017 | 43.54M |
| March 31, 2017 | -24.19M |
| December 31, 2016 | -21.60M |
| September 30, 2016 | 0.955M |
| June 30, 2016 | 81.68M |
| March 31, 2016 | 96.62M |
| December 31, 2015 | -2.295M |
| September 30, 2015 | 43.53M |
| June 30, 2015 | 26.42M |
| March 31, 2015 | 40.52M |
| December 31, 2014 | 81.64M |
| September 30, 2014 | 46.92M |
| June 30, 2014 | 13.04M |
| March 31, 2014 | 33.42M |
| December 31, 2013 | 54.95M |
| September 30, 2013 | 1.986M |
| June 30, 2013 | -1.38M |
| March 31, 2013 | -18.02M |
| December 31, 2012 | -14.20M |
| September 30, 2012 | 54.78M |
| June 30, 2012 | 5.619M |
| March 31, 2012 | -19.18M |
| December 31, 2011 | -41.84M |
| September 30, 2011 | -44.30M |
Free Cash Flow Range, Past 5 Years
-358.70M
Minimum
Jun 2023
395.00M
Maximum
Dec 2020
20.99M
Average
63.20M
Median
Sep 2022
Free Cash Flow Benchmarks
| Avid Bioservices Inc | -38.50M |
| Viking Therapeutics Inc | -54.87M |
| FibroGen Inc | -317.54M |
| Avinger Inc | -14.44M |
| RAPT Therapeutics Inc | -98.17M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 32.10M |
| Cash from Investing (Quarterly) | -11.40M |
| Cash from Financing (Quarterly) | 4.70M |
| Free Cash Flow Per Share (Quarterly) | 0.3973 |
| Free Cash Flow to Equity (Quarterly) | 22.30M |
| Free Cash Flow to Firm (Quarterly) | 40.41M |
| Free Cash Flow Yield | -258.3% |